These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


1479 related items for PubMed ID: 19996931

  • 1. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Orti G, Lowdell M, Fielding A, Samuel E, Pang K, Kottaridis P, Morris E, Thomson K, Peggs K, Mackinnon S, Chakraverty R.
    Transplantation; 2009 Dec 15; 88(11):1312-8. PubMed ID: 19996931
    [Abstract] [Full Text] [Related]

  • 2. CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study.
    Alyea EP, Canning C, Neuberg D, Daley H, Houde H, Giralt S, Champlin R, Atkinson K, Soiffer RJ.
    Bone Marrow Transplant; 2004 Jul 15; 34(2):123-8. PubMed ID: 15133487
    [Abstract] [Full Text] [Related]

  • 3. The association of CD25 expression on donor CD8+ and CD4+ T cells with graft-versus-host disease after donor lymphocyte infusions.
    Mutis T, Aarts-Riemens T, Verdonck LF.
    Haematologica; 2005 Oct 15; 90(10):1389-95. PubMed ID: 16219576
    [Abstract] [Full Text] [Related]

  • 4. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C, Torres A, García-Castellano JM, Roman J, Martin C, Serrano J, Falcon M, Alvarez MA, Gomez P, Martinez F.
    Bone Marrow Transplant; 1999 Mar 15; 23(5):443-50. PubMed ID: 10100557
    [Abstract] [Full Text] [Related]

  • 5. Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplantation.
    Baron F, Siquet J, Schaaf-Lafontaine N, Baudoux E, Hermanne JP, Fillet G, Beguin Y.
    Haematologica; 2002 Jan 15; 87(1):78-88. PubMed ID: 11801468
    [Abstract] [Full Text] [Related]

  • 6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May 15; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 7. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
    Peggs KS, Mackinnon S, Williams CD, D'Sa S, Thuraisundaram D, Kyriakou C, Morris EC, Hale G, Waldmann H, Linch DC, Goldstone AH, Yong K.
    Biol Blood Marrow Transplant; 2003 Apr 15; 9(4):257-65. PubMed ID: 12720218
    [Abstract] [Full Text] [Related]

  • 8. Individually adjusted prophylactic donor lymphocyte infusions after CD34-selected allogeneic peripheral blood stem cell transplantation.
    Ferrá C, Rodríguez-Luaces M, Gallardo D, Encuentra M, Martín-Henao GA, Peris J, Ancín I, Sarrá J, Berlanga JJ, García J, Grañena A.
    Bone Marrow Transplant; 2001 Nov 15; 28(10):963-8. PubMed ID: 11753552
    [Abstract] [Full Text] [Related]

  • 9. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF, Marijt EW, Barge RM, van Soest RA, Baas IO, Starrenburg CW, van Zelderen-Bhola SL, Fibbe WE, Smit WM, Willemze R, Falkenburg JH.
    Biol Blood Marrow Transplant; 2004 Mar 15; 10(3):204-12. PubMed ID: 14993886
    [Abstract] [Full Text] [Related]

  • 10. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD, Becker EE, Truitt RL.
    Biol Blood Marrow Transplant; 1999 Mar 15; 5(3):123-32. PubMed ID: 10392958
    [Abstract] [Full Text] [Related]

  • 11. Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8(+) T-cell count on day + 14 as a predictor of acute graft-versus-host disease.
    Petersen SL, Madsen HO, Ryder LP, Svejgaard A, Masmas TN, Dickmeiss E, Heilmann C, Vindeløv LL.
    Biol Blood Marrow Transplant; 2004 May 15; 10(5):337-46. PubMed ID: 15111933
    [Abstract] [Full Text] [Related]

  • 12. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).
    Michallet AS, Nicolini F, Fürst S, Le QH, Dubois V, Hayette S, Bourgeot JP, Tremisi JP, Thomas X, Gebuhrer L, Michallet M.
    Bone Marrow Transplant; 2005 Mar 15; 35(6):601-8. PubMed ID: 15756285
    [Abstract] [Full Text] [Related]

  • 13. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G, Truitt RL, Johnson BD.
    Biol Blood Marrow Transplant; 2006 Apr 15; 12(4):397-407. PubMed ID: 16545723
    [Abstract] [Full Text] [Related]

  • 14. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.
    Bloor AJ, Thomson K, Chowdhry N, Verfuerth S, Ings SJ, Chakraverty R, Linch DC, Goldstone AH, Peggs KS, Mackinnon S.
    Biol Blood Marrow Transplant; 2008 Jan 15; 14(1):50-8. PubMed ID: 18158961
    [Abstract] [Full Text] [Related]

  • 15. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.
    Zorn E, Wang KS, Hochberg EP, Canning C, Alyea EP, Soiffer RJ, Ritz J.
    Clin Cancer Res; 2002 Jul 15; 8(7):2052-60. PubMed ID: 12114403
    [Abstract] [Full Text] [Related]

  • 16. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
    Gallardo D, García-López J, Sureda A, Canals C, Ferra C, Cancelas JA, Berlanga JJ, Brunet S, Boqué C, Picón M, Torrico C, Amill B, Martino R, Martínez C, Martín-Henao G, Domingo-Albós A, Grañena A.
    Bone Marrow Transplant; 1997 Dec 15; 20(11):945-52. PubMed ID: 9422473
    [Abstract] [Full Text] [Related]

  • 17. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK, deMagalhaes-Silverman M, Hohl RJ, Hayashi M, Buatti J, Wen BC, Schlueter A, Strauss RG, Gingrich RD.
    Bone Marrow Transplant; 2003 Jan 15; 31(2):121-8. PubMed ID: 12621494
    [Abstract] [Full Text] [Related]

  • 18. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease.
    de Lima M, Bonamino M, Vasconcelos Z, Colares M, Diamond H, Zalcberg I, Tavares R, Lerner D, Byington R, Bouzas L, da Matta J, Andrade C, Carvalho L, Pires V, Barone B, Maciel C, Tabak D.
    Bone Marrow Transplant; 2001 Jan 15; 27(1):73-8. PubMed ID: 11244440
    [Abstract] [Full Text] [Related]

  • 19. Stable mixed chimerism after T cell-depleted allogeneic hematopoietic stem cell transplantation using conditioning with low-dose total body irradiation and fludarabine.
    Görner M, Kordelas L, Thalheimer M, Luft T, Pfeiffer S, Ustaoglu F, Punzel M, Weber-Nordt R, Moos M, Goldschmidt H, Ho AD.
    Bone Marrow Transplant; 2002 Apr 15; 29(7):621-4. PubMed ID: 11979314
    [Abstract] [Full Text] [Related]

  • 20. Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion.
    Soiffer RJ, Alyea EP, Hochberg E, Wu C, Canning C, Parikh B, Zahrieh D, Webb I, Antin J, Ritz J.
    Biol Blood Marrow Transplant; 2002 Apr 15; 8(11):625-32. PubMed ID: 12463482
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 74.